Despite this knowledge, individual or combination approaches to target PI3K, Akt, mTORC2, or IGF have not yet made any meaningful impact on advanced unresectable or metastatic PNET in the clinic. This evidence concerns the gene IGF1 and primitive neuroectodermal tumor.